Pilot Study of a Prophylactic Neopeptide Vaccine in Advanced ALK+ NSCLC
Conditions: NSCLC Stage IV; ALK Fusion Protein Expression Intervention: Biological: Peptide vaccine Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Non-Small Cell Lung Cancer | Research | Study | Vaccines